The molecular and cellular basis of iron toxicity in Iron Overload (IO) disorders. Diagnostic and therapeutic approaches

Zvi Ioav Cabantchik, Yan Sung Sohn, William Breuer, Breno Pannia Espósito

1Institute of Life Sciences, Hebrew University of Jerusalem, Safra Campus at Givat Ram; 2Israel and Instituto de Química, Universidade de São Paulo, São Paulo SP, Brasil

Introduction

Abnormal iron accumulation in human tissues and oxidative damage are emerging issues in the medical field (1,2). The most commonly recognized type of pathological accumulation has been associated with the general appearance of plasma non-transferrin bound iron (NTBI) (3-16) and particularly with a labile iron component that can infiltrate cells in an unregulated manner (17-19). A major consequence of excess iron accumulation is a rise in cellular labile iron (LCI) (4,8,10) that can promote the formation of reactive oxygen species (ROS) from physiological oxygen intermediates (ROI), overriding the cellular antioxidant machineries and causing oxidative damage (2,8,9,20). The major diseases caused by excess iron accumulation are those that result from tissue exposure to systemic rises in plasma NTBI, as in transfusional siderosis (sickle cell anemia, thalassemia major and some forms of myelodysplasia) or primary hemochromatosis and thalassemia intermedia (1,2). However, it is increasingly recognized that various neurological, hematological and more recently chronic diabetes and metabolic disorders may be caused by regional (cell or organ) rather than systemic iron accumulation (4,8,10,21). The regional iron accumulation results from mutations in genes or from humoral factors that affect particular components of cell iron metabolism leading to intracellular maldistribution of the metal (4,21). Iron accumulation of iatrogenic nature has recently been identified in the spleen, liver and pancreas of iv-iron supplemented CKD patients with chronic anemia (22).

The present review focuses on non-physiological (i.e. anomalous) forms of iron in plasma and cells that have been implicated in tissue iron accumulation and multi-organ iron overload and toxicity. Although those pathological forms have not been fully defined in chemical and toxicological terms, they have already been perceived as a major source of iron toxicity in systemic iron overload (SIO) disorders (1,2,6). In this review we explore the possibility that those pathological forms of iron might be of clinical value in the diagnosis of impending IO and in the monitoring of treatment efficacy.

Chemically labile iron as a diagnostic indicator in Systemic Iron Overload (SIO). SIO is a pathological condition characterized by persistently high levels of circulating and organ accumulated iron (2,6). Iron in plasma and interstitial fluids can exceed the effective iron binding capacity of circulating transferrin and generate chemical forms that are not associated with transferrin, hence the term non-transferrin bound iron (NTBI) (6,14,16,23-25). As NTBI has been causatively implicated in tissue IO, its level in plasma (or serum) could be perceived as marker/indicator of SIO (2,9) and therefore as a direct target of chelation (6,9,20,25). It would therefore seem appropriate and timely to discuss the potential clinical value of NTBI measurements in IO disorders, both on its own and in conjunction with the classical serum ferritin, and/or transferrin saturation. In fact, plasma ferritin has for many years served as the major, if not sole, clinical indicator of body iron status, largely because its levels were found empirically to reflect those of iron stored in reticuloendothelial system (RES) and/or liver, which in turn rely on measurements of liver iron concentration (LIC, classically measured in liver biopsies) (2,9). The advent of non-invasive iron scanning devices has gradually allowed tracing organ dysfunctions to excessively accumulated iron not only in liver, but also in heart and endocrine glands (9). The present view is that indicators of tissue IO directly reflect iron that accumulated over extended periods of time, while plasma ferritin reflects iron stores only in liver and spleen, though not uniquely (as also inflammatory conditions accompanied by functional iron deficiency lead to apparently similar changes in serum ferritin). On the other hand, the appearance of plasma NTBI can be perceived as an early indication of SIO per se and consequently of impending organ damage (6). This is because some NTBI forms present in plasma over extended periods of time can infiltrate cells where they may become chemically active and catalyze the generation of ROS that override cellular antioxidant capacities and thereby affect vital cell functions. These properties underlie the rationale of continuous maintenance of NTBI at basal levels as a tangible target in iron chelation therapy (10-12,15,26,27).

Non-transferrin-bound iron (NTBI)

Chemical nature and pathophysiological relevance in SIO. The fact that plasma NTBI is generally detected when spare transferrin binding capacity is diminished would indicate: a. that NTBI is generated at sites where apotransferrin levels might be limiting relative to the plasma infiltrated iron and b. that most/some of the NTBI formed might remain in plasma essentially inaccessible to circulating apotransfer-
The NTBI that is detected in plasma appears in various chemical forms, depending how much and from where (gut or RES) the excess iron originated, the patient’s history of transfusions or phlebotomies (as reflected in the degree of oxidative modifications of circulating proteins), and the ongoing chemical treatments (e.g., chelation). At present it is not clear which is the pathological threshold of NTBI, both as an indicator of IO per se and/or as a potential source of cell iron toxicity. Moreover, whether or not the NTBI forms in plasma/interstitial fluids will evoke organ (particularly extra-hepatic) iron accumulation and ensuing damage in thalassemia or hemochromatosis, would depend on three factors: a) the nature and concentration of the permeating species; b) the existence of cell membrane routes through which particular NTBI forms can (opportunistically) gain access into particular cells; and c) the time of exposure to those NTBI forms. Given the above factors, the relative contribution of specific routes to IO in particular tissues is likely to vary enormously, compounded by the fact that NTBI can appear as free organic iron complexes (28,29) or complexes that are non-specifically associated with plasma proteins (7,23,25,29). For the free complexes, the relevant plasma NTBI permeating components are either: a. the ionic and free ligand-metal, in which case its ingress might require metal reduction by membrane associated reductases followed by opportunistic translocation of the free-iron via putative transporters or channels (that can handle only free or hydrated divalent ions) or b. organic-iron complex, in which case more complex machineries that can handle iron-ligands should be implicated. If the major permeating species are the protein-bound iron complexes, then their tissue ingress would be limited to bulk endocytotic routes (mostly adsorptive endocytosis) followed by intracellular metal release (19). Clearly, a serial or parallel combination of the above mechanisms, bulk and ionic transport, can possibly account for the handling of all NTBI forms present in the different conditions of IO. However, the relative contribution of particular agencies to NTBI uptake into cells might differ among tissues, depending on the available repertoire of transporters/channels via which the locally available NTBI forms. Possible candidates for NTBI transport are the metal transporter ZIP14, voltage dependent Ca channels and transporters of organic acids that can also handle iron-chelates, but definitive demonstration is still pending (9).

Definition of NTBI The term NTBI was introduced in order to define non-physiological, low molecular weight forms of iron that appear in plasma or other body fluids of iron overloaded patients and are not tightly associated with transferrin (14,16). The presence of such forms was postulated on the basis that the amount of iron detected in plasma of IO patients often supersedes the plasma transferrin binding capacity (TIBC). However, as the original detection of NTBI in human sera necessitated extraction with mild chelators followed by size filtration (14,16,23,28,30), its native chemical identity in plasma was hampered. Although a major fraction of NTBI is considered redox active (13,31), hitherto, no single component of NTBI has been shown experimentally to be toxic in plasma per se. However, at particular NTBI levels, some components might indeed pose a biological risk as they can slowly infiltrate cells and override their ability to: a) safely absorb the incoming metal and/or b) neutralize their pro-oxidative capacity (17,19,20,32). Thus, although the term NTBI per se is simple and intuitive, it is both too broad and rather ambiguous. For instance, although NTBI by its very nature should comprise also ferritin, whose levels in plasma also rise in pathological SIO (2), it is customary to exclude it irrespective of its iron content. Conversely, chemically stable chelates of iron that are formed during chelation therapy and qualify stricto sensu as NTBI (and even measured as NTBI by some assays (5,23,33,34), should be excluded if the chelated iron is not redox active and poses no biological threat. Similarly, synthetic iron-polymer complexes that are administered parenterally, and qualify as NTBI despite being iatrogenic, are not considered bona fide NTBI because they are neither toxic in plasma or to the organism as a whole.

Definition of Labile plasma iron (LPI) and labile cell iron (LCI). Due to the ambiguities inherent in the term NTBI, we opted for designating the potentially toxic forms of iron in biological systems as labile iron, which in plasma we refer to as LPI and in cells as LCI (8-11). The labile iron comprises the redox-active and exchangeable forms of the metal as they appear in their native milieu and, by their very nature, they are also the direct targets of chelators (10,13). In normal physiological conditions, plasma and interstitial fluids are essentially devoid of labile iron (as long as there is sufficient transferrin iron binding capacity) whereas cells maintain a physiological pool of labile iron (LCI), usually at the sub-µM level (8,10) (Figure 1). With the appearance of plasma NTBI associated with SI, there is a concomitant rise in labile plasma iron (LPI) and, in turn, also in LCI, which is derived from long term cell exposure to the former. LCI levels can also change as a result of cell iron maldistribution that is found in pathological conditions associated with inappropriate cell handling of iron (4). The latter is caused by mutations in genes of iron metabolism (e.g. Friedreich ataxia and some forms of sideroblastic anemias) and also by humoral factors that affect iron import/export balance in some cells (e.g. hepcidin on macrophages).

Determination of NTBI. As NTBI in various IO conditions represents less than 1/10 the value of plasma TBI at full saturation (40-50 µM), its detection poses some analytical challenges. NTBI appears in plasma bound to small or oligomeric organic ligands (such as citrate) which, in turn, might be either freely filterable or adsorbed to proteins (25,28,29). This heterogeneity forced analytical assays to incorporate extraction/mobilization and filtration steps for complete determination of NTBI, while sparring TBI (14,16,23) (Figure 2). In the clinical setting, the chemical analysis of NTBI is generally preceded by freezing, storing and thawing of sera (or heparinized plasma), steps that ideally should preserve the native TBI and NTBI components. Although most available analytical methods are sensitive and reliable (particularly when no iron chelates are present in patient’s plasma), they are relatively laborious and not suited for the clinical setting.

LPI (labile plasma iron) and DCI (directly chelatable iron) as redox-active and chelatable forms of NTBI (5-8,13) The type of plasma NTBI that is potentially toxic to cells is comprised of iron that can be depot ed on cell surfaces as redox-active species and/or excessively taken up by cells in forms that can raise the labile cell iron (LCI). As labile forms are also potentially chelatable, they represent the primary pharmacological target of any chelation treatment aimed at preventing undesirable iron overloading of cells. Unlike the NTBI assays that were...
designed to reveal all forms of plasma NTBI using extraction-filtration procedures, the LPI and DCI assays (Figure 3) were designed to reveal labile and/or chelatable forms of iron in native biofluids while avoiding potential complications associated with addition of very high concentrations of iron-mobilizing agents.

The LPI assay (13,27,35) detects the ability of iron in plasma (or any other fluid, extra- or intra-cellular) to be prompted by physiological concentrations of ascorbic acid and catalytically oxidize the non-fluorescent dihydrorhodamine (DHR) into the fluorescent rhodamine (R)(Figure 3). The detected change in fluorescence of DHR prompted by ascorbate is attributed to labile iron insofar as the process is depressed or eliminated by a specific iron chelator which is added to the system in a parallel reaction.

The DCI assay (5) detects labile iron with a fluorescent chelator (free or coupled to a polymeric bead) that binds the metal with high affinity and stoichiometrically undergoes a commensurate quenching of the fluorescence (Figure 3). As with the LPI assay, the excess addition of a chelator (with no tag) provides the means to ascertain that the changes in fluorescence can be attributed solely to labile iron and are quantifiable with appropriate iron standards. Changes in fluorescence in biological samples can be followed in spectrofluorimeters or fluorescence plate readers and also in flow cytometers (or FACS machines) with the aid of probes coupled to beads.

Both LPI and DCI are applied as high throughput assays in formats based on fluorescence plate readers. As these assays use no exogenous mobilizing/extraction agent, some (cryptic) NTBI forms might not be detected due to being bound/adsorbed to proteins and/or of low redox-activity and/or limited accessibility to the iron-detector agents (7). Those cryptic forms can be revealed with the aid of agents that gently mobilize adsorbed NTBI labile species while minimally interfering with plasma components (Figure 3)(7). That was found necessary for detecting NTBI in highly oxidized plasma of hypotransfused-non-chelated thalassemia patients (7), but its pathophysiological significance is unclear. We found that the inclusion of moderate concentrations of a mild mobilizer (e.g. 0.1-0.5 mM nitrilotriacetic acid, NTA) not only increased the sensitivity of LPI or DCI assays but also reduced possible cumulative interferences by albumin, citrate and uric acid in different patient samples (7).

Importantly, the adopted modification caused no release of iron from fully saturated transferrin (TBI) or iron chelates like deferrioxamine (DFO), nor from the relatively weaker chelator deferiprone (DFP) or deferiprone (DFR) (7). The original and the modified methods, namely without or with the mobilizing agent; are referred as LPI and eLPI (‘e’ for enhanced or extracted LPI) and DCI and eDCI (enhanced or extracted DCI). Both eLPI and eDCI were highly correlated with each other and are perceived essentially as equivalent to NTBI (7).

Adaptation of DCI and LPI measurements to flow cytometry. A prototype method was developed in order to expand the scope of applications of DCI measurements and render the latter more accessible to clinical laboratories where flow cytometers (FACS technology) are essential instrumentation. The principle is essentially based on recruiting chelatable iron from biofluids via microsphere beads coated uniformly with a fluorescence metal sensor that senses the metal while binding to it with high affinity from diluted samples. The measurement of the bead-associated fluorescence in a flow cytometer (or equivalent instrument-FACS: fluorescence activated cell sorter) permits the assessment of changes in signal intensity that reflect binding of chelatable iron. Besides the sensitivity of the method which is comparable to DCI and LPI, it is less susceptible to interferences by medium components, allowing its application to plasma and serum alike, urine, cerebrospinal fluid, body exudates, saliva, etc. The bead technology has two modalities that cover:

Measurement of DCI in fluids with the aid of beads and flow cytometry (DCIB) (36) (Figure 4). The DCIB probes are microspheres or beads of defined size that are constructed of derivatized polystyrene onto which a dendrimer derivatized with both the fluorophore fluorescein (Fl) or rhodamine (R) and the chelator DFO are coupled covalently by a cross-linker. The resulting fluorescent DFO beads (FDB for fluorescein +DFO and RDB for rhodamine+ DFO beads) are calibrated for iron sensitivity with solutions containing iron saturated plasma/serum or urine or simple iron standards in buffered saline solution. The changes in fluorescence are attributed specifically to iron based on the...
fact that addition of excess amount of the iron chelator deferrioxamine (DFO) to samples essentially eliminates the contribution of the metal. Thus only the DFO-preventable change in signal is taken as equivalent to the presence of a given concentration of iron. A minimal concentration of mobilizing agent (NTA 0.1 mM) might be used to increase somewhat the sensitivity of the assay by extracting iron adsorbed to proteins or citrate present in samples.

Measurement of LCI levels in living cells by flow cytometry (18,32,37,38) (Figure 5). The labile cell iron content of cells (LCI) represents transitory forms of the metal that are redox active, exchangeable and chelatable and therefore are the most pertinent physiological, pharmacologically and toxicologically (8,10). LCI is typically determined in living cells with the probe calcein (green CALG or blue CALB) which is loaded into cells via permeant acetomethoxy-precursors CALG-AM or CALB-AM. The intracellularly released (and trapped) probe interacts with resident labile iron and undergoes quenching commensurate with LCI, which in turn is revealed by addition of a permeant iron chelator, as exemplified in Figure 5 for K562 cells. The green fluorescent CALG generated intracellularly from CALG-AM fills the cytosolic and nuclear space of cells and upon addition of permeant chelator (SIH or DFP) there is a rise in fluorescence F corresponding to CALG-Fe released by the chelator. With the aid of appropriate calibration curves,
LCI can be calculated from ΔF, as described elsewhere (8). The analogous measurement of LCI can be done by flow cytometry, by estimating ΔF from the mean fluorescence intensity (FL1-H) values before and after the addition of the permeant chelator SIH. The mean change in fluorescence intensity elicited by a permeant chelator (SIH or DFP) on blood samples containing erythrocytes and reticulocytes preloaded with CAL-AM is obtained from the difference in median intensity values (from plots as those shown above for fluorescence associated with each cell population determined with appropriate instrument settings, lower panel). For flow cytometry, the conversion of ΔF into actual LCI concentrations necessitates calibration with CALG-coated beads that are titrated with known amounts of iron. Those in turn are measured in the flow cytometer before and after addition of a strong chelator that can displace the CALG-bead bound iron.

Examples of applications of LPI and DCI in clinical trials of different chelators used for following treatment of thalassemia intermedia (Figure 6) and major (Figure 7) and myelodysplastic syndrome (MDS) (Figure 8). For the treatment of hemochromatosis by phlebotomy see Ref. 9.

LPI in thalassemia intermedia (β-thal/HbE) patients (Figure 6). Correlation between LPI and classical parameters of IO in pre-chelated patients (upper Figure) and in the course of treatment with deferoxamine (DFP).

The upper figure shows how LPI levels determined prior to initiation of treatment are correlated with those of serum ferritin (SF), transferrin (TT) saturation and red blood cell membrane (RBCm) iron. A study published in preliminary form (39) showed a strong correlation between LPI and LCI (measured by R2* MRI) in thalassemia major patients (n=83) following different chelation protocols.

The lower left figure shows the % change in blood parameters following 16 months of treatment (filled bars). The numbers in the bars indicate the number of months required for attaining a reduction of 50% in the indicated parameter. The lower right figure shows the kinetics of LPI, SF (serum ferritin) and RBCm (red blood cell membrane iron) and % transferrin saturation (all in relative units) during the course of treatment with DFP (daily a total of 50 mg/kg in 2 doses 12 h apart). The LPI depicts morning trough or basal levels of LPI, following the longest daily period following intake of chelator. LPI essentially declined fastest, followed by RBCm and SF.

LPI in β-thalassemia major (Figure 7). Daily and intermittent follow-up of patients treated with different chelators (compiled and modified from Ref. 12 and 19). LPI in thalassemia major patients was followed hourly during an entire day of chelation with various chelators (upper Figure) and a different group of patients treated daily with DFR and analyzed every 4-6 weeks at trough levels of DFR following (Figure 7 lower panel).

**Conclusions**

From a pathophysiological standpoint, LPI represents the major component in plasma causatively associated with tissue iron accumulation and ensuing overload. LCI in circulating blood cells, while not directly affected by IO, provides a measure for the amount of cell accumulated iron due to prolonged exposure to LPI. A major aspect of IO addressed in this review was the evaluation of LPI and LCI in circulating blood cells as merely another indication for overt IO or whether their analysis could provide an early indication: a) diagnostically, for impending/新兴IO and b) therapeutically, for assessing chelation efficacy. First and foremost, we emphasized that LPI and LCI should be viewed as dynamic parameters that are affected, respectively by: a) the outpour of iron into plasma or infiltration into cells (inherently related to the disease or of iatrogenic origin-as iv iron supplementation) and b) their utilization (natural or induced) or their neutralization by natural components, added chelators or venesecting therapies. Thus unlike...
ferritin that in serum (in the absence of inflammation) provides a systemic measure for long term iron accumulation/depletion in the RES (liver and spleen), LPI provides an instantaneous measure of labile iron in plasma and LCI in circulating blood cells.

In summary, we propose the measurement of LPI as follows:

- **diagnostically** (for assessing overt SIO), after a suitable washout period (from chelator or venesection, applicable);
- **therapeutically** (for assessing chelation efficacy), in two modalities:
  - a) as single LPI measurement taken at trough chelator levels in plasma (~24 h after administration of DFR, 10-12 h of DFP and 12-14 h of DFO); this provides a measure for the ability to maintain LPI at basal levels (<0.2±0.1 μM) at a given day in the course of chelation treatment of thalassemia major, thalassemia intermedia, SCD or MDS patients or a regimen of venesection applied to hemochromatosis patients.
  - b) as repeated (bimonthly) LPI measurements at trough chelator levels in the course of treatment as indication for attainment of basal levels as therapeutic target.

It was found that adherence to a treatment that maintains LPI at basal levels for an extended time period predicts the eventual reduction in liver IO parameters (LIC and SF). Although >80% of thalassemia major patients (n=40) with cardiac conditions had LPI >0.4 μM, a causative association between cardiomyopathies and exposure to a particular level of LPI/NTBI for a given period time, remains to be established for all forms of systemic IO (persistent plasma Tf sat >70%).

**References**

17. Glickstein, H, Ben El, R., Shvartsman M. and and Z. Ioav

Figure 8. LPI in MDS patients treated with different chelators (compiled from Ref. 15 and 26).
Cabantchik. Intracellular labile iron pools as direct targets of iron chelators. Blood. 2005 106: 3242-3250


